139 related articles for article (PubMed ID: 28426905)
21. RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Kaya G; Saxer-Sekulic N; Kaya A; Sorg O; Boespflug A; Thomas L; Saurat JH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1368-1372. PubMed ID: 29575357
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma.
Velter C; Libenciuc C; Routier E; Mateus C; Fahmy J; Ghoufi L; Lambotte O; Not A; Cauquil C; Claveau S; Claveau J; Robert C
Eur J Cancer; 2019 Apr; 111():8-11. PubMed ID: 30798086
[No Abstract] [Full Text] [Related]
23. A Rare Cause of Uveitis: Vemurafenib.
Sızmaz S; Görkemli N; Esen E; Demircan N
Turk J Ophthalmol; 2018 Dec; 48(6):323-325. PubMed ID: 30605942
[TBL] [Abstract][Full Text] [Related]
24. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
25. Acantholytic dyskeratotic acanthoma: a variant of a benign keratosis.
Ko CJ; Barr RJ; Subtil A; McNiff JM
J Cutan Pathol; 2008 Mar; 35(3):298-301. PubMed ID: 18251744
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?
Olteanu C; Scope A; Steinberg-Silman Y; Ziv M; Shear NH; Dodiuk-Gad RP; Markel G
Int J Dermatol; 2020 May; 59(5):e139-e141. PubMed ID: 32212333
[No Abstract] [Full Text] [Related]
27. Central retinal vein occlusion associated with vemurafenib use in metastatic skin melanoma.
Yang SY; Chen SN
Kaohsiung J Med Sci; 2018 Sep; 34(9):535-536. PubMed ID: 30173784
[No Abstract] [Full Text] [Related]
28. [Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Boiché M; Conart JB; Angioi-Duprez K
J Fr Ophtalmol; 2018 Jun; 41(6):e291-e292. PubMed ID: 29908650
[No Abstract] [Full Text] [Related]
29. BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis.
Singh AG; Tchanque-Fossuo CN; Elwood H; Durkin JR
Dermatol Online J; 2020 Feb; 26(2):. PubMed ID: 32239892
[TBL] [Abstract][Full Text] [Related]
30. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
31. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Tsuboi S; Yoshino K; Yamaguchi K; Imafuku K; Ohara K
J Dermatol; 2017 May; 44(5):607-608. PubMed ID: 27334634
[No Abstract] [Full Text] [Related]
32. Acantholytic dyskeratotic acanthoma: A rare and underappreciated entity.
Doh JY; Lee JH; Bang CH
Indian J Dermatol Venereol Leprol; 2023; 89(6):904-907. PubMed ID: 37317765
[No Abstract] [Full Text] [Related]
33. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2017 Sep; 44(9):e226-e227. PubMed ID: 28439948
[No Abstract] [Full Text] [Related]
34. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
[TBL] [Abstract][Full Text] [Related]
35. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.
Chen P; Chen F; Zhou B
Clin Exp Dermatol; 2019 Apr; 44(3):243-251. PubMed ID: 30280426
[TBL] [Abstract][Full Text] [Related]
36. Multiple acantholytic dyskeratotic acanthomas in a liver-transplant recipient.
Kanitakis J; Gouillon L; Jullien D; Ducroux E
Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046909
[TBL] [Abstract][Full Text] [Related]
37. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
38. Acantholytic dyskeratotic acanthoma: case report and review of the literature.
Goldenberg A; Lee RA; Cohen PR
Dermatol Pract Concept; 2014 Jul; 4(3):25-30. PubMed ID: 25126453
[TBL] [Abstract][Full Text] [Related]
39. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
40. Acantholysis caused repeated hemorrhagic bullae in a case of acantholytic acanthoma.
Minakawa S; Matsuzaki Y; Nakano H; Sawamura D; Elenitsas R
J Dermatol; 2012 Dec; 39(12):1107-8. PubMed ID: 22568826
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]